BFRA - Biofrontera AG

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Biofrontera AG

Hemmelrather Weg 201
Leverkusen 51377
Germany
49 214 87 63 20
http://www.biofrontera.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees149

Key Executives

NameTitlePayExercisedYear Born
Prof. Hermann LübbertCo-Founder, Chairman of Management Board & CEON/AN/A1956
Mr. Thomas SchafferCFO & Member of Management BoardN/AN/A1963
Mr. Christoph DünwaldChief Commercial Officer, Head of Sales & Marketing and Additional Member of Management BoardN/AN/A1968
Mr. Alexander RichardsonHead of UK Sales TeamN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

Corporate Governance

Biofrontera AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.